薬理と治療

Abstract

Objectives　We have evaluated the short︱term safety and effectiveness of Nexala® in patients with gonarthrosis and coxarthrosis; Nexala®, a formulation containing Theracurmin®（highly bioavailable curcumin）, Akbamax®（enriched boswellic acid extract）and Vitamin D3（Cholecalciferol）. Methods　30 patients were selected, 20 were recruited and all 20 completed the study. Treatment with Nexala® was well tolerated and did not produce any adverse effects. Results　The formulation of Nexala®（2 capsules x day）reduced pain, stiffness and improved functionality significantly（P＜0.0001）after a 28-day period of continuous treatment measured by WOMAC and the Lequesne Index. Conclusions　Nexala® shows great potential for the treatment of patients with arthrosis; its short-term effectiveness as well as its tolerability profile makes it an ideal candidate when we need to decrease pain and inflammation and improve functionality in patients with gonarthrosis and coxarthrosis.